TRENDS-integrated WCD management provided actionable physiologic data, detecting symptom exacerbation in 31% of patients, with a mean daily wear-time of 21.3 hours similar to historical controls.
Cohort (n=66)
Does the TRENDS remote monitoring function integrated into a wearable cardioverter-defibrillator improve clinical utility and individualized management compared to historical controls in patients with WCD indications?
The integration of the TRENDS remote monitoring system into wearable cardioverter-defibrillators provides actionable physiologic and patient-reported data that supports individualized cardiovascular management.
Background: Wearable cardioverter-defibrillators (WCDs) are equipped with the TRENDS remote-monitoring system, enabling continuous assessment of arrhythmias, physiological parameters, and patient-reported outcomes. This study evaluated the clinical utility of TRENDS-integrated WCD management and compared it with a historical control. Methods: We prospectively analyzed 36 consecutive patients who received a WCD with TRENDS between 2019 and 2024 and compared them with 30 historical controls treated before the implementation of TRENDS. Results: The WCD indications were heart failure as primary prevention (64%) and acute coronary syndrome with ventricular arrhythmias (28%). Among 18 patients who met the criteria for an implantable cardioverter-defibrillator (ICD), including 1 patient with WCD shock, 9 ultimately underwent ICD implantation. The mean daily WCD wear-time was 21.3 h and did not differ significantly from that of the historical control. The response rate to health-related questionnaires was 89%. TRENDS detected symptom exacerbation in 31% of patients, weight gain in 19% of patients, and missed medication in 19% of patients. Daily step-count was significantly lower in patients with ICD indications than in those without (5012 ± 2980 steps vs. 7977 ± 3584 steps, p = 0.01). TRENDS data also aided in initiating anticoagulation therapy and optimizing beta-blocker therapy. Conclusions: TRENDS provided clinically actionable physiologic and patient-reported information that supported individualized cardiovascular management.
Ikeda et al. (Mon,) conducted a cohort in Heart failure or acute coronary syndrome with ventricular arrhythmias requiring WCD (n=66). TRENDS-integrated WCD management vs. Historical controls (WCD without TRENDS) was evaluated on Mean daily WCD wear-time. TRENDS-integrated WCD management provided actionable physiologic data, detecting symptom exacerbation in 31% of patients, with a mean daily wear-time of 21.3 hours similar to historical controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: